These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1714647)

  • 1. Notes on FK 506.
    Starzl TE; Fung J; Todo S; Tzakis A
    Transplant Proc; 1991 Aug; 23(4):2178-9. PubMed ID: 1714647
    [No Abstract]   [Full Text] [Related]  

  • 2. Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts.
    Murase N; Fujisaki S; Tanabe M; Tsamandas AC; Todo S; Starzl TE; Demetris AJ
    Transplant Proc; 1994 Jun; 26(3):1517-8. PubMed ID: 7518139
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens.
    Tsugita M; Valdivia LA; Celli S; Pan F; Sun H; Demetris AJ; Fung JJ; Starzl TE
    Transplant Proc; 1995 Feb; 27(1):277. PubMed ID: 7533393
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of transplant rejection in the presence of cytomegalovirus viremia.
    O'Hair DP; Johnson CP; Roza AM; Adams MB
    Transplant Proc; 1990 Aug; 22(4):1815-7. PubMed ID: 2167537
    [No Abstract]   [Full Text] [Related]  

  • 5. Overview of FK506 in transplantation.
    Fung JJ; Abu-Elmagd K; Todo S; Shapiro R; Tzakis A; Jordan M; Armitage J; Jain A; Alessiani M; Martin M
    Clin Transpl; 1990; ():115-21. PubMed ID: 1715740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts.
    Lautenschlager I; Höckerstedt K; Mäkisalo H; Orko R; Taskinen E
    Transplant Proc; 1991 Aug; 23(4):2233-5. PubMed ID: 1714650
    [No Abstract]   [Full Text] [Related]  

  • 7. FK 506 for liver, kidney, and pancreas transplantation.
    Starzl TE; Todo S; Fung J; Demetris AJ; Venkataramman R; Jain A
    Lancet; 1989 Oct; 2(8670):1000-4. PubMed ID: 2478846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.
    Fung JJ; Todo S; Tzakis A; Demetris A; Jain A; Abu-Elmaged K; Alessiani M; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):14-21. PubMed ID: 1703682
    [No Abstract]   [Full Text] [Related]  

  • 9. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506.
    Murase N; Kim DG; Todo S; Cramer DV; Fung J; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):74-5. PubMed ID: 1689906
    [No Abstract]   [Full Text] [Related]  

  • 11. Negative control of the number of F cells by the immune system of the adult.
    Fuhr JE; Goldman MH
    Ann N Y Acad Sci; 1991; 628():256-7. PubMed ID: 1712554
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunologic significance of hepatocytes in tolerance induction after liver transplantation.
    Nakano H; Nakajima Y; Segawa M; Kanehiro H; Murao Y; Nakagawa K; Shiratori T
    Transplant Proc; 1987 Feb; 19(1 Pt 1):511-3. PubMed ID: 3274815
    [No Abstract]   [Full Text] [Related]  

  • 13. FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts.
    Pan F; Valdivia LA; Tsugita M; Celli S; Haeuchi K; Demetris AJ; Avci G; Fung JJ
    Transplant Proc; 1994 Jun; 26(3):1211. PubMed ID: 7518113
    [No Abstract]   [Full Text] [Related]  

  • 14. FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates.
    Hildebrandt A; Meiser B; Human P; Reichenspurner H; Rose A; Odell J; Reichart B
    Transplant Proc; 1991 Feb; 23(1 Pt 1):509-10. PubMed ID: 1703694
    [No Abstract]   [Full Text] [Related]  

  • 15. A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation.
    Armitage JM; Kormos RL; Griffith BP; Hardesty RL; Fricker FJ; Stuart RS; Marrone GC; Todo S; Fung J; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1149-52. PubMed ID: 1703336
    [No Abstract]   [Full Text] [Related]  

  • 16. Quality assessment of cyclosporine monitoring--Canadian validations.
    Wong PY; Mee AV; Glenn J; Keown PA
    Transplant Proc; 1990 Jun; 22(3):1216-7. PubMed ID: 2349683
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunosuppression for organ grafting.
    Calne RY
    Transplant Proc; 1991 Aug; 23(4):2175-7. PubMed ID: 1714646
    [No Abstract]   [Full Text] [Related]  

  • 18. Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts.
    Flavin T; Ivens K; Wang J; Gutierrez J; Hoyt EG; Billingham M; Morris RE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):531-2. PubMed ID: 1703701
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms of protection from humoral rejection by a xenografted liver.
    Celli S; Valdivia LA; Kelly RH; Sun H; Tsugita M; Pan F; Rao AS; Demetris AJ; Fung JJ; Starzl TE
    Transplant Proc; 1995 Feb; 27(1):300-2. PubMed ID: 7533395
    [No Abstract]   [Full Text] [Related]  

  • 20. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis.
    Carrier M; Jenicek M; Pelletier LC
    Transplant Proc; 1992 Dec; 24(6):2586-91. PubMed ID: 1465874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.